Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy-Reference-Cited by-同舟云学术

Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy

Published:2017-03 Issue: Volume:388 Page:292-302
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Bharti Rashmi,Dey Goutam,Banerjee Indranil,Dey Kaushik Kumar,Parida Sheetal,Kumar B.N. Prashanth,Das Chandan Kanta,Pal Ipsita,Mukherjee Manabendra,Misra Mridula,Pradhan Anjan K.,Emdad Luni,Das Swadesh K.,Fisher Paul B.,Mandal Mahitosh

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. Microbial amphiphiles: a class of promising new-generation anticancer agents;Dey;Drug Discov. Today,2015

2. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer;Ataie-Kachoie;Cytokine Growth F. R.,2013

3. Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: a snapshot of IL-6 mediated involvement;Bharti;Cancer Lett.,2016

4. Interleukin-6 in bone metastasis and cancer progression;Ara;Eur. J. Cancer,2010

5. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers;Yao;Pharmacol. Ther.,2014

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A holistic review of recent advances in nano-based drug delivery systems for the treatment of triple-negative breast cancer (TNBC);Journal of Nanoparticle Research;2024-05

2. Repurposing diacerein to suppress colorectal cancer growth by inhibiting the DCLK1/STAT3 signaling pathway;Chinese Journal of Natural Medicines;2024-04

3. The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review;Biomedicines;2024-03-05

4. Somatostatin receptor2 (SSTR2) expression, prognostic implications, modifications and potential therapeutic strategies associates with head and neck squamous cell carcinomas;Critical Reviews in Oncology/Hematology;2024-01

5. Liposome-based nanomedicines for cancer immunotherapy;Nanomedicine in Cancer Immunotherapy;2024